The latest shake-up at the FDA forced out the top two officials in charge of reviewing cell and gene therapies, analysts said.

Shares of gene editing companies were largely steady in the premarket on Friday after the FDA’s Center for Biologics Research ...

We look at the continued turmoil within the FDA, including the forced dismissal of top gene therapy regulator Nicole Verdun, ...